Here we described a RAS mutation (RasG37 mutant) model of progressive prostate cancer that is associated with EGFR signaling activation and miR-203 inhibition, leading to the up-regulation of EGFR ligands. This evidence concerns the gene EGFR and prostate carcinoma.